Fig. 4
From: Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease
Abiraterone, similarly to E2, facilitates ER-transactivation and ER-degradation via the proteasome. a wt-MCF7 (b) and MCF7-LTEDY537C were transfected with the EREII-tk-luc construct and treated for 16 h with E2, abiraterone, ICI or in combination in the presence or absence of MG-132 (10 μM). Data is representative of two biological experiments with three replicates for each treatment. Bars represent ±SEM. c Tandem ubiquitin-binding entity (TUBE) followed by immunoblot detection of ubiquitin and ER was carried out in wt-MCF7 and MCF7-LTEDY537C, treated for 16 h with E2 or abiraterone in the presence or absence of MG-132 (10 μM). d Concomitant Western blot analysis of ER and TFF1 assessed after 16 h treatment with E2 or abiraterone in the presence or absence of MG-132 (10 μM)
